论文部分内容阅读
目的:观察对原发性肝癌术前患者采取消癌平注射液治疗效果及其对机体免疫功能影响。方法:选取2011年1月—2013年6月收治的原发性肝癌术前患者72例作为研究对象,按照数字随机法分为两组,每组36例,观察组一般支持治疗基础上采取消癌平注射液治疗,对照组采取护肝、间断补充蛋白质等最佳支持治疗,观察两组患者疗效及治疗后机体T细胞免疫功能相关指标CD3、CD4、CD8及NK细胞活性变化。结果:两组治疗前AFP水平无明显差异,P>0.05;治疗后AFP水平(4167±754)ng/m L,明显低于对照组(4975±742)ng/m L,P<0.05;观察组治疗后CD3、NK细胞活性分别为(71.9±13.9)%、(46.6±12.6)%,活性显著优于对照组,P<0.05,且观察组治疗后CD4、CD8细胞活性与对照组比较有显著差异。结论:消癌平注射液治疗原发性肝癌可明显提高机体免疫功能,增强患者自身抵抗力,具有重要临床价值。
Objective: To observe the therapeutic effect of Xiaojianping injection on preoperative patients with primary liver cancer and its effect on immune function. Methods: Seventy-two patients with primary hepatocellular carcinoma (HCC) preoperatively admitted from January 2011 to June 2013 were enrolled in this study. The patients were divided into two groups according to the number randomization method, with 36 cases in each group. On the basis of general supportive therapy, Cancer injection, the control group to take the liver, intermittent supplementation of protein and other best supportive treatment, the efficacy and treatment of two groups were observed after treatment T cell immune function related indicators CD3, CD4, CD8 and NK cell activity changes. Results: There was no significant difference of AFP level between the two groups before treatment (P> 0.05). The level of AFP in the two groups after treatment (4167 ± 754 ng / m L) was significantly lower than that in the control group (4975 ± 742 ng / m L, P <0.05) The activity of CD3 and NK cells in the treatment group were (71.9 ± 13.9)% and (46.6 ± 12.6)%, respectively, which were significantly better than those in the control group (P <0.05). The activity of CD4 and CD8 in the observation group was Significant differences. Conclusion: Xiao-ping injection for the treatment of primary liver cancer can significantly improve immune function and enhance their own resistance, has important clinical value.